Product Brochure

Your Product Innovation Begins Here: Booth 4555

Overview

EffePharm will showcase innovative anti-aging solutions, including UthPeak™ reduced NMN (NMNH), the first Self-GRAS approved, US patent-pending reduced NMN. Backed by the largest and longest clinical trial, demonstrating an impressive 5-year age reversal.

In addition to NMNH, we will present other premium anti-aging offerings such as MitoAge™ Urolithin A, along with exciting new innovations in our weight management sector.

Discover our clinically proven liposomal products designed for enhanced absorption and efficacy, featuring LipoAvail™ liposomal NAD+ and LipoAvail™ liposomal glutathione.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Latest Content

NMN supplementation proved to mitigate radiotherapy-induced damages

Paid for by Effepharm Ltd

Scientific study validates NMN’s efficacy in alleviating intestinal damages caused by radiotherapy through reducing alterations to gut bacteria composition and function.

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”

Related Resources

Uthever® NMN: Novel Food Approval Nearing Final Stage

20-Apr-2026

Paid for by Effepharm Ltd

White Paper

One Step Away from EU Market Compliance for NMN. The official positive opinion of Novel Food is expected to be published shortly, which means Uthever® NMN will be the first compliant ingredient.